SABCS 2023盛幕将启,中国之声汇总!(2)

作者:肿瘤瞭望   日期:2023/11/29 11:27:45  浏览量:1320

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

第46届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥举行,SABCS作为乳腺癌领域规模最大,最具影响力的国际性会议,届时多项重磅研究结果将在会上公布。《肿瘤瞭望》现将中国专家投稿摘要号及题目进行汇总(Poster Sessions部分排名不分先后),如有遗漏或错误,欢迎广大读者后台留言。

编者按:第46届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥举行,SABCS作为乳腺癌领域规模最大,最具影响力的国际性会议,届时多项重磅研究结果将在会上公布。《肿瘤瞭望》现将中国专家投稿摘要号及题目进行汇总(Poster Sessions部分排名不分先后),如有遗漏或错误,欢迎广大读者后台留言。
 
Poster Sessions
 
专场:POSTER SESSION 1
时间:12月6日12:00 pm-2:00 pm
地点:Halls 2-3
?
PO1-01-02 Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course trastuzumab/pertuzumab for HER2-positive breast cancer:a single-arm,phase II study
脂质体阿霉素/环磷酰胺作为HER2阳性乳腺癌的新辅助化疗,随后序贯紫杉与全疗程曲妥珠单抗/帕妥珠单抗:一项单臂,Ⅱ期研究的最终分析
第一作者:Yaping Yang(中山大学孙逸仙纪念医院)
 
PO1-01-04 The optimal neoadjuvant treatment regimen for HR+/HER2+breast cancer:a network meta-analysis.
HR+/HER2+乳腺癌的最佳新辅助治疗方案:一项网状荟萃分析
第一作者:Hao Wang(电子科技大学医学院附属肿瘤医院;四川省肿瘤医院)
 
PO1-03-11 Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer:A Multicenter,OpenLabel,Randomized Controlled Study.
卡瑞利珠单抗联合白蛋白结合型紫杉醇和卡铂对比白蛋白结核型紫杉醇和卡铂作为三阴性乳腺癌新辅助治疗:一项多中心、开放标签、随机对照研究
第一作者:赵伟鹏(天津医科大学肿瘤医院)
 
PO1-04-04 Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer:a single-arm phase 2 trial
伊尼妥单抗联合吡咯替尼和口服长春瑞滨治疗HER2阳性转移性乳腺癌患者:一项单臂2期试验
第一作者:黄香(江苏省人民医院)
 
PO1-04-05 Effectiveness and safety of inetetamab+pyrotinib+vinorelbine in≥second-line treatment of HER2-positive metastatic breast cancer
伊尼妥单抗+吡咯替尼+长春瑞滨在HER2阳性转移性乳腺癌患者二线及以上治疗中的有效性和安全性
第一作者:吴凡(福建省肿瘤医院)
 
PO1-05-11 Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer:a retrospective cohort study
二甲双胍辅助治疗新发转移性乳腺癌的疗效:一项回顾性队列研究
第一作者:Ren Chongxi(沧州中西医结合医院)
 
PO1-06-01 Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer
肿瘤类器官引导治疗局部晚期不可切除或转移性乳腺癌的临床疗效
第一作者:Ying-Yi Lin(广东省人民医院)
 
PO1-06-05 Heterogeneity and prognostic characteristics of HER2-low breast cancer:A retrospective analysis of patients with HER2-negative metastatic breast cancer
HER2低表达乳腺癌的异质性和预后特征:对HER2阴性转移性乳腺癌患者的回顾性分析
第一作者:律慧敏(河南省肿瘤医院)
 
PO1-06-07 EMSY enhances cancer stem cell self-renewal and tumorigenesis by reshaping methionine metabolism in triple-negative breast cancer
EMSY通过重塑三阴性乳腺癌的蛋氨酸代谢来增强癌症干细胞的自我更新和肿瘤发生
第一作者:刘翠翠(复旦大学附属肿瘤医院)
 
PO1-06-10 Overall survival results from EVER-132-001,a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer
EVER-132-001:sacituzumab govitecan治疗中国转移性三阴性乳腺癌患者的2b期单臂研究
第一作者:马飞(中国医学科学院肿瘤医院)
 
PO1-06-11 Exosomal HMGB1 induce PD-L1+-tumor associated macrophages through glycometabolic reprogramming to promote lung-tropic metastasis of triple negative breast cancer
外泌体HMGB1通过糖代谢重编程诱导PD-L1+肿瘤相关巨噬细胞,促进三阴性乳腺癌向肺转移
第一作者:Wei-xian Chen(常州市第二人民医院)
 
PO1-06-12 Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer.
sitravatinib+替雷利珠单抗联合或不联合nab-紫杉醇治疗局部复发或转移性三阴性乳腺癌患者的II期研究
第一作者:范蕾(复旦大学附属肿瘤医院)
 
PO1-07-03 An Accurate Breast Cancer Diagnosis Method Using a Multi-Feature Fusion Neural Network on Contrast-Enhanced Spectral Mammography
基于多特征融合神经网络的对比增强乳房X线造影的准确诊断方法
第一作者:Yipeng Song(烟台毓璜顶医院)
 
PO1-07-04 Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer.
多组学分析揭示了PD-L1在三阴性乳腺癌中的表达格局
第一作者:Han Wang(复旦大学附属肿瘤医院)
 
PO1-07-07 Radiomics features for distinguishing true recurrence versus new primary tumor following breast-conserving treatment
放射组学特征用于区分保乳治疗后真正复发与新发原发肿瘤
第一作者:Feilin Qu(复旦大学附属肿瘤医院)
 
PO1-07-11 Radiogenomic-based imaging intratumor heterogeneity model predicts breast cancer prognosis and unveils therapeutic targets
基于放射基因组学成像的肿瘤内异质性模型预测乳腺癌预后并揭示治疗靶点
第一作者:Guan-Hua Su(复旦大学附属肿瘤医院)
 
PO1-08-05 Using the CTS5 Score to Predict Late Recurrence in Male and Female Estrogen ReceptorPositive Breast Cancer Patients:a SEER database analysis of 65,729 cases
使用CTS5评分预测男性和女性ER阳性乳腺癌患者的晚期复发风险:65729例SEER数据库分析
第一作者:Fenhua Wang(杭州临平区妇幼保健院)
 
PO1-11-12 Factors associated with treatment failure for chemotherapy-induced nausea and vomiting(CINV)among breast cancer patients receiving adjuvant chemotherapy.
接受辅助化疗的乳腺癌患者化疗引起的恶心和呕吐(CINV)治疗失败的相关因素
第一作者:Winnie Yeo(香港中文大学)
 
PO1-13-01 Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study
MONARCH plus和monarch E研究中接受阿贝西利治疗的中国乳腺癌患者的安全性
第一作者:邵志敏(复旦大学附属肿瘤医院)
 
PO1-13-05 Genomic characteristics and its therapeutic implications in breast cancer patients with detectable molecular residual disease
具有可检测分子残留乳腺癌患者的基因组特征及其治疗意义
第一作者:徐琰(重庆大坪医院)
 
PO1-13-11 ZNF689 promotes homologous recombination via NBS1 ubiquitination and its loss confers sensitivity to PARP inhibition in triple-negative breast cancer
ZNF689通过NBS1泛素化促进同源重组,ZNF689缺失使其在三阴性乳腺癌中对PARP抑制敏感
第一作者:Li-Ping Ge(复旦大学附属肿瘤医院)
 
PO1-13-12 Mechanistic Analysis and Potential Therapeutic Implications in Breast Cancer with Fibrotic Focus
乳腺癌伴纤维化灶的机制分析及潜在治疗意义
第一作者:Canbin Fang(香港中文大学)
 
PO1-14-03 Discovery of proliferation essential gene signature and ACTL6A as potential biomarker for predicting prognosis and neoadjuvant therapy response in triple-positive breast cancer
发现增殖必需基因标记和ACTL6A作为预测三阳性乳腺癌预后和新辅助治疗反应的潜在生物标志物
第一作者:Xiaofen Li(福建省肿瘤医院)
 
PO1-14-06 Integrated analysis reveals the impact of obesity on triple-negative breast cancer
综合分析揭示了肥胖对三阴性乳腺癌的影响
第一作者:Yue Gong(复旦大学附属肿瘤医院)
 
PO1-14-07 Programme of mast cell subsets to potentiate breast cancer immunotherapy:from bed to bench to bed(the phase 2 platform RENAISSANCE trial)
肥大细胞亚群增强乳腺癌免疫治疗方案:从床到长凳再到床(2期平台RENAISSANCE试验)
第一作者:Song-Yang Wu(复旦大学附属肿瘤医院)
 
PO1-15-02 Comprehensive characterization of genetic interactions in breast cancer reveals therapeutic vulnerabilities
乳腺癌基因相互作用的综合表征揭示了治疗的脆弱性
第一作者:Caijin Lin(复旦大学附属肿瘤医院)
 
PO1-15-07 Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2-breast cancer:a sub-study of the MULAN umbrella trial
在HR+/HER2-乳腺癌中,以亚型为导向的精准治疗方法,使传统的“一刀切”治疗方法得到了改进:MULAN伞式试验的一项亚研究
第一作者:Xiu-Zhi Zhu(复旦大学附属肿瘤医院)
 
PO1-15-08 Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy
三阴性乳腺癌转移的基因组特征表明PKD1是一种新的免疫治疗生物标志物
第一作者:Xiu-Zhi Zhu(复旦大学附属肿瘤医院)
 
PO1-15-09 Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2-Breast Cancer
维生素A代谢诱导铁下垂增强HR+/HER2-乳腺癌对免疫治疗的效果
第一作者:Yi-Fan Zhou(复旦大学附属肿瘤医院)
 
PO1-16-03 GDP-mannose enhances the efficacy of PARP inhibitors and immunotherapy in triplenegative breast cancer
GDP甘露糖可提高PARP抑制剂和免疫治疗在三阴性乳腺癌中的疗效
第一作者:Yi Xiao(复旦大学附属肿瘤医院)
 
PO1-16-09 Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
T1c-2N0-1M0的三阴性乳腺癌能从新辅助化疗中获益吗?
第一作者:Jie Zhang(福建医科大学附属协和医院)
 
PO1-17-01 Surgical Margins and prognosis of borderline and malignant phyllodes tumors of breast
乳腺交界性及恶性叶状瘤的手术切缘及预后
第一作者:甘露(重庆医科大学附属第一医院)
 
PO1-17-03 Real-world evidence of Trastuzumab biosimilars in HER2-positive breast cancer:Evaluating utilization,efficacy,and safety in Taiwan
曲妥珠单抗生物类似药治疗HER2阳性乳腺癌的真实证据:评估中国台湾的利用率、有效性和安全性
第一作者:Yi-Hung Lo(高雄退伍军人总医院)
 
PO1-19-04 Dalpiciclib and tucidinostat in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors:A phase Ib trial
达尔西利+西达本胺治疗CDK4/6抑制剂耐药的HR+/HER2-晚期乳腺癌:一项Ib期试验
第一作者:王涛(解放军总医院第五医学中心)
 
PO1-22-08 Ductal Lavage versus Oral Corticosteroids in Patients with Idiopathic Granulomatous Mastitis:A Multicenter,Open-label,Randomized,Controlled,Non-inferiority Study.
导管灌洗与口服皮质类固醇治疗特发性肉芽肿性乳腺炎:一项多中心、开放标签、随机、对照、非劣效性研究
第一作者:Kai Chen(中山大学孙逸仙纪念医院)
 
PO1-22-09 Current margin assessment practice for breast-conserving surgery in China:a single institution audit
目前中国保乳手术的边缘评估实践:单一机构审计
第一作者:Feilin Qu(复旦大学附属肿瘤医院)
 
PO1-23-08 Exosome-based delivery of microRNAs confers adriamycin-resistance to sensitive cells through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer
在HER2阴性乳腺癌中,基于外泌体的microrna递送通过调节免疫和代谢相关基因PTEN,赋予敏感细胞阿霉素耐药性
第一作者:Sujin Yang(南京医科大学第一附属医院)
 
PO1-23-10 Multi-omics analysis identifies the mechanism in cross-resistance to endocrine therapy and CDK4/6 inhibitor in breast cancer
多组学分析确定了乳腺癌内分泌治疗和CDK4/6抑制剂交叉耐药的机制
第一作者:Ming-Feng Hou(高雄医科大学附属医院)
 
PO1-24-01 ADAR1 drives ribosomal biogenesis by regulating NOP14 and stabilizing FBL-NOP58 complex in breast cancer
ADAR1在乳腺癌中通过调节NOP14和稳定FBL-NOP58复合体驱动核糖体生物发生
第一作者:Liren Wangxu(复旦大学附属肿瘤医院)
 
PO1-25-04 PTN-positive luminal progenitors induce angiogenesis and metastasis in inflammatory breast cancer.
PTN阳性腔内祖细胞诱导炎性乳腺癌血管生成和转移
第一作者:Mengmeng Zhang(中山大学孙逸仙纪念医院)
 
PO1-27-01 Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer:A Multicenter,Randomized,Double-Blind,Parallel-Controlled Phase 3 Trial
比较TQB2440与帕妥珠单抗治疗HER2阳性早期或局部晚期乳腺癌的疗效和安全性:一项多中心、随机、双盲、平行对照的3期试验
第一作者:张清媛(哈尔滨医科大学附属肿瘤医院)
 
PO1-27-04 A Multi-center Randomized Phase II Study of Doxorubicin Liposome Versus Epirubicin Plus Cyclophosphamide Combined With Trastuzumab and Pertuzumab(HP)Followed by THP as Neoadjuvant Therapy for HER2-positive Early Breast Cancer
随机多中心Ⅱ期研究:脂质体阿霉素对比表柔比星加环磷酰胺联合曲妥珠单抗+帕妥珠单抗(HP)序贯THP作为HER2阳性早期乳腺癌新辅助治疗的效果
第一作者:夏雯(中山大学肿瘤防治中心)
 
PO1-27-05 De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer(HELEN-006):a randomized,phase 3 trial
一项随机3期试验,每周降低新辅助白蛋白紫杉醇剂量联合曲妥珠单抗+帕妥珠单抗治疗治疗HER2阳性早期乳腺癌(HELEN-006)
第一作者:刘真真(河南省肿瘤医院)
 
PO1-27-06:HER2 Amplification Level and Focal/Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer
HER2扩增水平和局部病灶/肿瘤大小作为HER2阳性乳腺癌新辅助化疗和抗HER2治疗反应的预测因子
第一作者:廖宁(广东省人民医院)
 
PO1-28-04 PILHLE-001:neoadjuvant pyrotinib combined with chemotherapy in HR-positive,HER2-low(IHC 2+/FISH-negative)early breast cancer.
PILHLE-001:吡咯替尼联合化疗新辅助治疗HR阳性、HER2低表达(IHC 2+/FISH阴性)的早期乳腺癌
第一作者:龚畅(中山大学孙逸仙纪念医院)
 
PO1-28-07 Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer(HNBC-001):results from a multicenter,randomized controlled,open-label phase II trial
多西他赛联合顺铂对比多西他赛联合阿霉素和环磷酰胺治疗早期三阴性乳腺癌(HNBC-001):一项多中心、随机对照、开放标签Ⅱ期试验的结果
第一作者:Dechuang Jiao(河南省肿瘤医院)
 
PO1-28-08 The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer(NeoSACT)
Ⅱ期新辅助研究:安罗替尼+sintilmab联合化疗治疗三阴性乳腺癌(NeoSACT)的疗效和安全性结果
第一作者:Liulu Zhang(广东省人民医院)
 
PO1-29-02 Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer.
HER2靶向双特异性抗体KN026联合多西他赛一线治疗HER2阳性复发/转移性乳腺癌的2.5年随访数据
第一作者:张清媛(哈尔滨医科大学附属肿瘤医院)
 
专场:POSTER SESSION 2
时间:12月6日5:00 pm-7:00 pm
地点:Halls 2-3
 
PO2-01-04 Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2-positive breast cancer:a network meta-analysis.
抗HER2治疗在HER2阳性乳腺癌新辅助治疗中的疗效和安全性:一项网络荟萃分析
第一作者:甘露(重庆医科大学附属第一医院)
 
PO2-01-05 Neoadjuvant pyrotinib plus trastuzumab,and chemoterapy in patients with HER2-positive early breast cancer:a real-world study
HER2阳性早期乳腺癌患者新辅助吡咯替尼+曲妥珠单抗和化疗:一项真实世界的研究
第一作者:Jun Zhou(江苏省连云港市第一人民医院)
 
PO2-02-05 CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive,HER2-negative stage II-III breast cancer:a single-arm exploratory trial
CDK4/6抑制剂达尔西利联合来曲唑作为激素受体阳性、HER2-的绝经后Ⅱ-Ⅲ期乳腺癌患者的新辅助治疗:一项单臂探索性试验
第一作者:Lina Zhang(河北医科大学第四医院)
 
PO2-02-07 Clinicopathological Features and Prognostic Role of HER2 Low in Early Breast Cancer:A real world study
HER2低表达早期乳腺癌的临床病理特征和预后作用:一项真实世界研究
第一作者:Ziqing Kong(解放军总医院第一医学中心)
 
PO2-03-05 Neoadjuvant anthracycline followed by Toripalimab combined with nab-paclitaxel in patients with stage IIA-IIIC triple negative breast cancer(NeoTENNIS):efficacy and safety results of a phase II study
新辅助蒽环类药物特瑞普利单抗联合白蛋白紫杉醇治疗ⅡA-ⅢC期三阴性乳腺癌(NeoTENNIS):一项Ⅱ期研究的疗效和安全性结果
第一作者:Min He(复旦大学附属肿瘤医院)
 
PO2-03-11 A novel peripheral CD4+T cell immune network associated with response to PD-1 inhibitor in early-stage triple negative breast cancer
一种新的外周血CD4+T细胞免疫网络与早期三阴性乳腺癌对PD-1抑制剂的反应相关
第一作者:Zehao Wang(复旦大学附属肿瘤医院)
 
PO2-04-02 Trends in Disparities and Transitions of target therapy in Patients With ERBB2 Positive Early Breast Cancer in China and the US,2011 to 2021.
2011年至2021年中国和美国HER2阳性早期乳腺癌患者靶向治疗的差异和转变趋势
第一作者:李健斌(解放军总医院第五医学中心)
 
PO2-04-03 BL-M07D1,an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors:Results from a first-in-human phase 1 study
BL-M07D1,一种针对HER2的抗体-药物偶联物,用于HER2阳性/低表达的局部晚期或转移性乳腺癌和其他实体瘤患者(人体首次1期研究的结果)
第一作者:宋尔卫(中山大学孙逸仙纪念医院)
 
PO2-04-07 Efficacy and Safety of First-line Therapy in Patients with HER-2 positive Advanced Breast Cancer:A network Meta-analysis of Randomized Controlled Trials
一线治疗HER2阳性晚期乳腺癌患者的疗效和安全性:随机对照试验的网络meta分析
第一作者:junxiao wang(三明市第二医院)
 
PO2-05-01 Famitinib,a multi-targeted receptor tyrosine kinase inhibitor,combined with dalpicilib and fulvestrant in advanced HR-positive and HER2-negative breast cancer
法米替尼(一种多靶点受体酪氨酸激酶抑制剂)联合达尔西利和氟维司群治疗晚期HR+/HER2-乳腺癌
第一作者:闫敏(河南省肿瘤医院)
 
PO2-05-08 ISM5043,a novel,selective KAT6 inhibitor for the treatment of advanced and refractory ER+breast cancer
ISM5043,一种新型的选择性KAT6抑制剂,用于治疗晚期难治性ER+乳腺癌
第一作者:Xin Cai(英科智能)
 
PO2-05-12 Retrospective analysis on therapeutic efficacy and predictive indicators of eribulin plus anti-angiogenic drugs for metastatic breast cancer.
艾立布林联合抗血管生成药物治疗转移性乳腺癌的疗效及预测指标回顾性分析
第一作者:Junmei Zhang(西安国际医学中心医院)
 
PO2-05-13 HER2 status presented an unstable switching from primary to recurrent breast cancer
HER2状态呈现出从原发性乳腺癌到复发性乳腺癌的不稳定转换
第一作者:Anjie Zhu(北京大学肿瘤医院)
 
PO2-06-09 A prospective phase 2 study on efficacy and safety of AK105,anlotinib combined with nabpaclitaxel(nab-P)as a first-line therapy in patients(pts)with advanced triple-negative breast cancer(TNBC)
一项前瞻性2期研究:AK105、安罗替尼联合白蛋白紫杉醇作为晚期三阴性乳腺癌(TNBC)患者一线治疗的疗效和安全性
第一作者:Liang Zhang(辽宁省肿瘤医院)
 
PO2-06-11 A phase II randomized trial of gemcitabine plus cisplatin(GP)vs gemcitabine plus carboplatin(GC)as the first-line treatment for patients with metastatic triple-negative breast cancer
吉西他滨加顺铂(GP)对比吉西他滨加卡铂(GC)作为转移性三阴性乳腺癌患者一线治疗的Ⅱ期随机试验
第一作者:Chengcheng Gong(复旦大学附属肿瘤医院)
 
PO2-06-14 Kynurenine induces senescence reprogramming to promote metastasis in young triplenegative breast cancer
犬尿氨酸诱导衰老重编程促进年轻三阴性乳腺癌的转移
第一作者:刘翠翠(复旦大学附属肿瘤医院)
 
PO2-08-02 Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
评价雄激素受体表达在新辅助化疗治疗的乳腺癌亚型中的预测和预后价值
第一作者:张瑾(天津医科大学肿瘤医院)
 
PO2-13-04 Single cell characterization of senescent CD8+T cell promotes immunotherapy resistance in early-stage triple-negative breast cancer
衰老CD8+T细胞单细胞特性促进早期三阴性乳腺癌免疫治疗耐药
第一作者:Tong Fu(复旦大学)
 
PO2-15-02 Personalized circulating tumor DNA(ctDNA)monitoring can early identify disease progression and predict prognosis in patients with breast cancer undergoing neoadjuvant therapy
在接受新辅助治疗的乳腺癌患者中,个性化循环肿瘤DNA(ctDNA)监测可以早期识别疾病进展并预测预后
第一作者:刘运江(河北医科大学第四医院)
 
PO2-16-06 Treatment Patterns of Neoadjuvant Therapy in Chinese Patients with HR-Positive/HER2-Positive Early or Locally Advanced Breast Cancer:A Real-World Study Using NCID Data in 2019-2022
中国HR+/HER2+早期或局部晚期乳腺癌患者的新辅助治疗模式:2019-2022年使用NCID数据的真实世界研究
第一作者:刘真真(河南省肿瘤医院)
 
PO2-16-08 Adjuvant Treatment Selection for County-Level Patients with HR+/HER2-Early Breast Cancer in a Real-Life Setting in China.
中国县级HR+/HER2-早期乳腺癌患者的辅助治疗选择
第一作者:Yinghua Ji(新乡医学院第一附属医院)
 
PO2-17-03 Patient reported outcomes(PROs)and survival with toremifene versus aromatase inhibitors(AI)in patients with moderate/high-risk premenopausal hormone receptor(HR)-positive breast cancer:A real-world study
托瑞米芬对比芳香酶抑制剂(AI)在中/高危绝经前HR+乳腺癌患者中应用的患者报告结局(PROs)和生存率:一项真实世界研究
第一作者:Yaping Yang(中山大学孙逸仙纪念医院)
 
PO2-17-04 Landscape of young breast cancer under 35 years in China over the past decades:a multicentre retrospective cohort study(YBCC-Catts study)
近几十年来中国35岁以下年轻乳腺癌的发展状况:一项多中心回顾性队列研究(YBCC-Catts研究)
第一作者:王雪(中国医学科学院肿瘤医院)
 
PO2-18-12 Updated Results of a Phase II Study:Neoadjuvant Inetetamab Combined with Pertuzumab,Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer
一项Ⅱ期研究的最新结果:新辅助伊尼妥单抗联合帕妥珠单抗、紫杉醇和卡铂治疗局部晚期HER2阳性乳腺癌
第一作者:Yue Chai(中国医学科学院肿瘤医院)
 
PO2-23-06 Clinical study of stained region lymph node biopsy(SrLNB)in axillary surgery after neoadjuvant systemic therapy in patients with axillary lymph node positive breast cancer
腋窝淋巴结阳性乳腺癌新辅助全身治疗后腋窝手术染色区淋巴结活检(SrLNB)的临床研究
第一作者:Jue Wang(南京医科大学附属第一医院)
 
PO2-23-08 High intratumor heterogeneity induced PSME2 confers endocrine resistance via ERαPARylation in hormone receptor-positive and HER2-negative breast cancer
在HR+/HER2-乳腺癌中,高肿瘤内异质性诱导的PSME2通过ERαPARylation赋予内分泌耐药
第一作者:Li-Ping Ge(复旦大学附属肿瘤医院)
 
PO2-23-11 SMAD4 depletion contributes to endocrine therapy resistance by ERBB signaling in HR+HER2-breast cancer
在HR+/HER2-乳腺癌中,SMAD4缺失通过ERBB信号促进内分泌治疗耐药
第一作者:Kang Li(重庆医科大学附属第一医院)
 
PO2-24-12 Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic antigenic peptides
肿瘤特异性环状RNA通过编码隐性抗原肽引发抗肿瘤免疫应答
第一作者:Di Huang(中山大学孙逸仙纪念医院)
 
PO2-25-02 The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triplenegative breast cancer
微生物代谢物三甲胺N-氧化物促进三阴性乳腺癌的抗肿瘤免疫
第一作者:Hai Wang(复旦大学附属肿瘤医院)
 
PO2-25-04 Anti-TIGIT upregulate CD226 on CD8+T cell as a potential therapeutic manner in HER2 positive breast cancer
抗TIGIT上调CD8+T细胞上的CD226作为HER2阳性乳腺癌的潜在治疗方式
第一作者:Liyi Zhang(复旦大学附属肿瘤医院)
 
PO2-27-11 Antitumor efficacy and safety of sacibertinib(Hemay022)in combination with endocrine therapy in patients with ER+and HER2+metastatic breast cancer:A phase Ib study
Sacibertinib(Hemay022)联合内分泌治疗ER+/HER2+转移性乳腺癌患者的抗肿瘤疗效和安全性:一项Ⅰb期研究
第一作者:李惠平(北京大学肿瘤医院)

 

 

 

 

版面编辑:张靖璇  责任编辑:无医学编辑

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多